Eli Lilly and Company secured a federal court order against pharmacy groups in Florida and Tennessee for an alleged $200 million fraud scheme.
The network reportedly exploited the rebate program for the diabetes and weight-loss drug Trulicity since 2020.
Defendants submitted hundreds of thousands of false rebate claims for non-existent patients and prescriptions.
The scheme involved purchasing Trulicity to resell on the secondary market while simultaneously claiming fraudulent rebates.
A U.S. District Judge in Miami issued a temporary restraining order to stop further claims and prevent the destruction of records.